Kevin Healy,
Jan Fandrianto and Selfia Halim Distinguished Professorship in Engineering,
University of California, Berkeley
Kevin E. Healy, Ph.D. is the Jan Fandrianto and Selfia Halim Distinguished Professor in Engineering at the University of California at Berkeley in the Departments of Bioengineering, and Materials Science and Engineering. He served as Chair of the Department of Bioengineering from 2011 to 2015. He is a thought leader and innovator working at the interface between stem cells and materials science to develop dynamic engineered systems to explore both fundamental biological phenomena and new applications in translational medicine. His group currently conducts research in the areas of: bioinspired stem cell microenvironments to control stem cell lineage specification and self-organization into microtissues or organoids; bioinspired systems for regenerative medicine; biological interfaces; and, microphysiological systems for drug development, gene editing, and environmental toxicity screening. Professor Healy is an elected Fellow of AIMBE, AAAS, FBSE, BMES, and recently received an Alexander von Humboldt Foundation Award. He has chaired the Gordon Research Conference on Biomaterials and Biocompatibility, and has been honored with the 2011 Clemson award for outstanding contributions to basic biomaterials science. He is a named inventor on numerous issued United States and international patents relating to biomaterials, therapeutics, stem cells, and medical devices, and has founded several companies to develop these systems for applications in biotechnology and regenerative medicine.
Human Tissue Chips for Drug Development, Disease Modeling, and More…
Monday, 14 October 2019 at 12:00
Add to Calendar ▼2019-10-14 12:00:002019-10-14 13:00:00Europe/LondonHuman Tissue Chips for Drug Development, Disease Modeling, and More…3D-Printing in the Life Sciences in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
Our work has emphasized creating both healthy and diseased model organ systems, we call microphysiological systems or ‘tissue chips’, to address the costly and complex drug discovery process. The average time to develop and launch a new drug in the United States is 10-15 years, and costs ~ $2-5b. The poor efficiency and high failure rates are attributed to the heavy reliance on non-human animal models employed during safety and efficacy testing that poorly reflect human disease states. With the discovery of human induced pluripotent stem cells, we can now develop tissue chips to be used for high content drug screening, disease modelling, and numerous other applications. While tissue chips are poised to disrupt the drug development process and significantly reduce the cost of bringing a new drug candidate to market, tissue chip technology is much more robust and creates a whole new paradigm in how to conduct biological science, and advances medicine in revolutionary ways. Ultimately, the vision is to reduce or eliminate the use of animals in drug discovery, and conduct ‘clinical trials’ in patient-specific tissue chips that can accommodate variations in genetics, environment, and lifestyle.
Add to Calendar ▼2019-10-14 00:00:002019-10-15 00:00:00Europe/London3D-Printing in the Life Sciences3D-Printing in the Life Sciences in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2019-10-14 12:00:002019-10-14 13:00:00Europe/LondonHuman Tissue Chips for Drug Development, Disease Modeling, and More…3D-Printing in the Life Sciences in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
.jpg)